3种方案治疗慢性盆腔炎的药物经济学分析

Pharmacoeconomics of 3 Therapeutic Schemes for Chronic Pelvic Inflammation

目的:评价3种方案治疗慢性盆腔炎的经济学效果。方法:126例慢性盆腔炎患者按治疗方案随机分为A组(美洛西林+替硝唑+依替米星)、B组(头孢他啶+替硝唑+微波)、C组(左氧氟沙星+替硝唑+桂枝茯苓胶囊),3组治疗均为2个疗程,2疗程之间间歇20d。结果:A、B、C组医疗总成本分别为(3813.3±502.9)、(3476.4±311.0)、(2690.0±166.4)元,总有效率分别为92.11%、94.59%、97.44%,成本-效果比分别为41.45、36.59、27.73;以C组为参照,A、B组增量成本-效果比分别为—225、—393;C组复发率(5.13%)显著低于A、B组的23.68%、24.32%(P<0.005)。结论:C方案有明显的经济学优势。

OBJECTIVE： To evaluate the economic efficacy of three therapeutic schemes for chronic pelvic inflammation. METHODS： A total of 126 patients with chronic pelvic inflammation were randomly divided into 3 groups： Group A＇ was assigned to receive Mezlocillin plus Tinidazole and Etimlcin; Group B to receive Ceftazidime plus Tinidazole and microwave, and Group C to receive Levofloxacin, Tinidazole and Guizhi Fuling Capsule. All 3 groups received 2 courses of treatment with intermission of 20 days between 2 periods. RESULTS- The total costs of 3 groups （A, B and C） were 3 813.3± 502.9 yuan, 3 476.4 ± 311.0 yuan and 2 690.0 ± 166.4 yuan, respectively. The total effective rates of 3 groups were 92.11%, 94.59% and 97.44%, respectively. Cost- effectiveness ratios were 41.45, 36.59 and 27.73, respectively. The incremental cost- effectiveness ratios of Group A and Group B were negative 225 and negative 393 in accordance with Group C, respectively. The relapse rate in Group C （5.13%） was significantly lower than that in Group A （23.68%） and Group B （24.32%）（P〈0.005）. CONCLUSION： Scheme C manifests significant economic superiority.